Cancer Research UK and KisoJi Biotechnology have launched a new Phase I/IIa clinical trial for people with selected TROP2-expressing solid tumours. 

The study will evaluate the effectiveness and safety of KisoJi’s lead asset, KJ-103, a naked anti-TROP2 antibody. 

TROP2 is a transmembrane glycoprotein involved in multiple signalling pathways linked to the movement and spread of cancer cells. It is expressed across a range of cancer types, particularly epithelial cancers. TROP2 expression is associated with advanced disease, tumour metastasis, and poorer patient outcomes. 

The trial will investigate increasing dose levels to determine the dose(s) for further evaluation, and will assess the preliminary efficacy of KJ-103. KJ-103 will be studied both as monotherapy in patients with a variety of solid tumours and also when given alongside standard of care pembrolizumab in participants with locally advanced, unresectable, or metastatic head and neck cancer. 

Unlike antibody-drug conjugates (ADCs), KJ-103 does not contain a cytotoxic payload. Instead, it functions by recruiting immune cells to kill tumour cells. It uses TROP2 to direct macrophage activation and phagocytosis of tumour cells expressing the target, leading to tumour cell death. 

KJ-103 may offer an alternative treatment option for people with TROP2-expressing cancers where TROP2 ADCs have proved ineffective or are unsuitable due to their toxicity profile. 

Dr David Young, Co-Founder and CEO of KisoJi said: “We are very excited to offer a different way of treating cancer with KJ-103. Our partners at Cancer Research UK are crucial to developing this drug, which is the first of its kind coming out of our technology. Validating KJ-103 in these trials leads not only to new options for these patients, but provide impetus for developing other novel drugs from our suite of technologies.”